Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data
Large-scale data are still lacking on the relationship between serum prolactin concentration and dopamine D2 receptor occupancy in patients with schizophrenia treated with antipsychotics. The dataset from 481 subjects (risperidone, N=172, olanzapine, N=211, and ziprasidone, N=98) who participated in...
Gespeichert in:
Veröffentlicht in: | Progress in neuro-psychopharmacology & biological psychiatry 2013-08, Vol.45, p.178-182 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 182 |
---|---|
container_issue | |
container_start_page | 178 |
container_title | Progress in neuro-psychopharmacology & biological psychiatry |
container_volume | 45 |
creator | Tsuboi, Takashi Bies, Robert R. Suzuki, Takefumi Mamo, David C. Pollock, Bruce G. Graff-Guerrero, Ariel Mimura, Masaru Uchida, Hiroyuki |
description | Large-scale data are still lacking on the relationship between serum prolactin concentration and dopamine D2 receptor occupancy in patients with schizophrenia treated with antipsychotics.
The dataset from 481 subjects (risperidone, N=172, olanzapine, N=211, and ziprasidone, N=98) who participated in Phase 1 of the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) was used in the present analysis. Dopamine D2 receptor occupancy levels on the day of the measurement of serum prolactin level were estimated from plasma antipsychotic concentrations. A multivariate general linear model was used to examine effects of clinical and demographic characteristics, including estimated D2 occupancy levels, on serum prolactin concentrations. Individual subjects were divided into two groups, stratified by the presence of hyperprolactinemia. To evaluate the performance of this binary classification, sensitivity, specificity, and accuracy of consecutive cut-off points in the D2 occupancy were calculated.
The multivariate general linear model revealed that estimated D2 occupancy levels had significant effects on serum prolactin concentrations while any other variables failed to show significant effects. The cut-off point associated with 0.5 or greater, in both sensitivity and specificity with the greatest accuracy, was 73% (sensitivity, 0.58; specificity, 0.68; accuracy=0.64) (68–70% for risperidone, 77% for olanzapine, and 55% for ziprasidone.).
The threshold for hyperprolactinemia in D2 occupancy may lie somewhat on a lower side of the established therapeutic window with antipsychotics (i.e. 65–80%). This finding highlights the need for the use of the lowest possible dose to avoid this hormonal side effect in the treatment of schizophrenia.
•We evaluated the relationship between hyperprolactinemia and dopamine D2 occupancy.•The dataset from patients with schizophrenia in the CATIE was used.•D2 receptor occupancy was estimated from plasma concentrations of antipsychotics.•The threshold for hyperprolactinemia in dopamine D2 occupancy was found to be 73%.•The threshold was 68–70% for risperidone, 77% olanzapine, and 55% ziprasidone. |
doi_str_mv | 10.1016/j.pnpbp.2013.05.010 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1500791253</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S027858461300105X</els_id><sourcerecordid>1500791253</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-b6cacae5625b86918949b1d36ae48afeec6ab57dd5499e015e53de732c0943383</originalsourceid><addsrcrecordid>eNqFkU1vEzEQhi0EomnhFyAhX5C4JPhj7d1F4hCFQitV4lLO1qw9qzjaD2M7Remvx2kC3ODkkfyMPe88hLzhbMUZ1x92qzCFLqwE43LF1Ipx9owseFM3y0pw_ZwsmCi1aip9QS5T2jFWSCZfkgsha1FzqRbk8eYQMIY4D2Czn3D0QGFyFFP2I2R01M0BxnJDPwsa0WLIc6SztfsAkz1QP9EA2eOUE_3p85Ymu_WPc9hGnDx8pOsJhkPyic49zVukm_X97TV1kOEVedHDkPD1-bwi379c329ulnffvt5u1ndLW-k6LzttwQIqLVTX6JY3bdV23EkNWDXQI1oNnaqdU1XbIuMKlXRYS2FZW0nZyCvy_vRuSfljX4KZ0SeLwwATzvtkuGKsbrlQ8v9oxQUvk-iqoPKE2jinFLE3IZaNxYPhzBz9mJ158mOOfgxTpvgpXW_PH-y7Ed2fnt9CCvDuDECyMPSxLNmnv1ytWdvqY6hPJw7L5h48RpNskWDR-SIpGzf7fw7yC31dsBE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1412156264</pqid></control><display><type>article</type><title>Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Tsuboi, Takashi ; Bies, Robert R. ; Suzuki, Takefumi ; Mamo, David C. ; Pollock, Bruce G. ; Graff-Guerrero, Ariel ; Mimura, Masaru ; Uchida, Hiroyuki</creator><creatorcontrib>Tsuboi, Takashi ; Bies, Robert R. ; Suzuki, Takefumi ; Mamo, David C. ; Pollock, Bruce G. ; Graff-Guerrero, Ariel ; Mimura, Masaru ; Uchida, Hiroyuki</creatorcontrib><description>Large-scale data are still lacking on the relationship between serum prolactin concentration and dopamine D2 receptor occupancy in patients with schizophrenia treated with antipsychotics.
The dataset from 481 subjects (risperidone, N=172, olanzapine, N=211, and ziprasidone, N=98) who participated in Phase 1 of the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) was used in the present analysis. Dopamine D2 receptor occupancy levels on the day of the measurement of serum prolactin level were estimated from plasma antipsychotic concentrations. A multivariate general linear model was used to examine effects of clinical and demographic characteristics, including estimated D2 occupancy levels, on serum prolactin concentrations. Individual subjects were divided into two groups, stratified by the presence of hyperprolactinemia. To evaluate the performance of this binary classification, sensitivity, specificity, and accuracy of consecutive cut-off points in the D2 occupancy were calculated.
The multivariate general linear model revealed that estimated D2 occupancy levels had significant effects on serum prolactin concentrations while any other variables failed to show significant effects. The cut-off point associated with 0.5 or greater, in both sensitivity and specificity with the greatest accuracy, was 73% (sensitivity, 0.58; specificity, 0.68; accuracy=0.64) (68–70% for risperidone, 77% for olanzapine, and 55% for ziprasidone.).
The threshold for hyperprolactinemia in D2 occupancy may lie somewhat on a lower side of the established therapeutic window with antipsychotics (i.e. 65–80%). This finding highlights the need for the use of the lowest possible dose to avoid this hormonal side effect in the treatment of schizophrenia.
•We evaluated the relationship between hyperprolactinemia and dopamine D2 occupancy.•The dataset from patients with schizophrenia in the CATIE was used.•D2 receptor occupancy was estimated from plasma concentrations of antipsychotics.•The threshold for hyperprolactinemia in dopamine D2 occupancy was found to be 73%.•The threshold was 68–70% for risperidone, 77% olanzapine, and 55% ziprasidone.</description><identifier>ISSN: 0278-5846</identifier><identifier>EISSN: 1878-4216</identifier><identifier>DOI: 10.1016/j.pnpbp.2013.05.010</identifier><identifier>PMID: 23727135</identifier><identifier>CODEN: PNPPD7</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Adult and adolescent clinical studies ; Aged ; Antipsychotic Agents - adverse effects ; Antipsychotic Agents - blood ; Antipsychotic Agents - pharmacology ; Benzodiazepines - adverse effects ; Benzodiazepines - blood ; Benzodiazepines - pharmacology ; Biological and medical sciences ; CATIE ; Data processing ; Dopamine D2 receptor occupancy ; Endocrinopathies ; Female ; Humans ; Hyperprolactinemia ; Hyperprolactinemia - blood ; Hyperprolactinemia - chemically induced ; Hyperprolactinemia - complications ; Hyperprolactinemia - metabolism ; Hypothalamus. Hypophysis. Epiphysis (diseases) ; Male ; Medical sciences ; Middle Aged ; Neuropharmacology ; Non tumoral diseases. Target tissue resistance. Benign neoplasms ; Pharmacology. Drug treatments ; Piperazines - adverse effects ; Piperazines - blood ; Piperazines - pharmacology ; Predictive Value of Tests ; Prolactin - blood ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychoses ; Receptors, Dopamine D2 - drug effects ; Risperidone - adverse effects ; Risperidone - blood ; Risperidone - pharmacology ; Schizophrenia ; Schizophrenia - blood ; Schizophrenia - complications ; Schizophrenia - metabolism ; Sensitivity and Specificity ; Thiazoles - adverse effects ; Thiazoles - blood ; Thiazoles - pharmacology</subject><ispartof>Progress in neuro-psychopharmacology & biological psychiatry, 2013-08, Vol.45, p.178-182</ispartof><rights>2013 The Authors</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-b6cacae5625b86918949b1d36ae48afeec6ab57dd5499e015e53de732c0943383</citedby><cites>FETCH-LOGICAL-c467t-b6cacae5625b86918949b1d36ae48afeec6ab57dd5499e015e53de732c0943383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.pnpbp.2013.05.010$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,778,782,3539,27911,27912,45982</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27609968$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23727135$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tsuboi, Takashi</creatorcontrib><creatorcontrib>Bies, Robert R.</creatorcontrib><creatorcontrib>Suzuki, Takefumi</creatorcontrib><creatorcontrib>Mamo, David C.</creatorcontrib><creatorcontrib>Pollock, Bruce G.</creatorcontrib><creatorcontrib>Graff-Guerrero, Ariel</creatorcontrib><creatorcontrib>Mimura, Masaru</creatorcontrib><creatorcontrib>Uchida, Hiroyuki</creatorcontrib><title>Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data</title><title>Progress in neuro-psychopharmacology & biological psychiatry</title><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><description>Large-scale data are still lacking on the relationship between serum prolactin concentration and dopamine D2 receptor occupancy in patients with schizophrenia treated with antipsychotics.
The dataset from 481 subjects (risperidone, N=172, olanzapine, N=211, and ziprasidone, N=98) who participated in Phase 1 of the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) was used in the present analysis. Dopamine D2 receptor occupancy levels on the day of the measurement of serum prolactin level were estimated from plasma antipsychotic concentrations. A multivariate general linear model was used to examine effects of clinical and demographic characteristics, including estimated D2 occupancy levels, on serum prolactin concentrations. Individual subjects were divided into two groups, stratified by the presence of hyperprolactinemia. To evaluate the performance of this binary classification, sensitivity, specificity, and accuracy of consecutive cut-off points in the D2 occupancy were calculated.
The multivariate general linear model revealed that estimated D2 occupancy levels had significant effects on serum prolactin concentrations while any other variables failed to show significant effects. The cut-off point associated with 0.5 or greater, in both sensitivity and specificity with the greatest accuracy, was 73% (sensitivity, 0.58; specificity, 0.68; accuracy=0.64) (68–70% for risperidone, 77% for olanzapine, and 55% for ziprasidone.).
The threshold for hyperprolactinemia in D2 occupancy may lie somewhat on a lower side of the established therapeutic window with antipsychotics (i.e. 65–80%). This finding highlights the need for the use of the lowest possible dose to avoid this hormonal side effect in the treatment of schizophrenia.
•We evaluated the relationship between hyperprolactinemia and dopamine D2 occupancy.•The dataset from patients with schizophrenia in the CATIE was used.•D2 receptor occupancy was estimated from plasma concentrations of antipsychotics.•The threshold for hyperprolactinemia in dopamine D2 occupancy was found to be 73%.•The threshold was 68–70% for risperidone, 77% olanzapine, and 55% ziprasidone.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Aged</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic Agents - blood</subject><subject>Antipsychotic Agents - pharmacology</subject><subject>Benzodiazepines - adverse effects</subject><subject>Benzodiazepines - blood</subject><subject>Benzodiazepines - pharmacology</subject><subject>Biological and medical sciences</subject><subject>CATIE</subject><subject>Data processing</subject><subject>Dopamine D2 receptor occupancy</subject><subject>Endocrinopathies</subject><subject>Female</subject><subject>Humans</subject><subject>Hyperprolactinemia</subject><subject>Hyperprolactinemia - blood</subject><subject>Hyperprolactinemia - chemically induced</subject><subject>Hyperprolactinemia - complications</subject><subject>Hyperprolactinemia - metabolism</subject><subject>Hypothalamus. Hypophysis. Epiphysis (diseases)</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Non tumoral diseases. Target tissue resistance. Benign neoplasms</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperazines - adverse effects</subject><subject>Piperazines - blood</subject><subject>Piperazines - pharmacology</subject><subject>Predictive Value of Tests</subject><subject>Prolactin - blood</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychoses</subject><subject>Receptors, Dopamine D2 - drug effects</subject><subject>Risperidone - adverse effects</subject><subject>Risperidone - blood</subject><subject>Risperidone - pharmacology</subject><subject>Schizophrenia</subject><subject>Schizophrenia - blood</subject><subject>Schizophrenia - complications</subject><subject>Schizophrenia - metabolism</subject><subject>Sensitivity and Specificity</subject><subject>Thiazoles - adverse effects</subject><subject>Thiazoles - blood</subject><subject>Thiazoles - pharmacology</subject><issn>0278-5846</issn><issn>1878-4216</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1vEzEQhi0EomnhFyAhX5C4JPhj7d1F4hCFQitV4lLO1qw9qzjaD2M7Remvx2kC3ODkkfyMPe88hLzhbMUZ1x92qzCFLqwE43LF1Ipx9owseFM3y0pw_ZwsmCi1aip9QS5T2jFWSCZfkgsha1FzqRbk8eYQMIY4D2Czn3D0QGFyFFP2I2R01M0BxnJDPwsa0WLIc6SztfsAkz1QP9EA2eOUE_3p85Ymu_WPc9hGnDx8pOsJhkPyic49zVukm_X97TV1kOEVedHDkPD1-bwi379c329ulnffvt5u1ndLW-k6LzttwQIqLVTX6JY3bdV23EkNWDXQI1oNnaqdU1XbIuMKlXRYS2FZW0nZyCvy_vRuSfljX4KZ0SeLwwATzvtkuGKsbrlQ8v9oxQUvk-iqoPKE2jinFLE3IZaNxYPhzBz9mJ158mOOfgxTpvgpXW_PH-y7Ed2fnt9CCvDuDECyMPSxLNmnv1ytWdvqY6hPJw7L5h48RpNskWDR-SIpGzf7fw7yC31dsBE</recordid><startdate>20130801</startdate><enddate>20130801</enddate><creator>Tsuboi, Takashi</creator><creator>Bies, Robert R.</creator><creator>Suzuki, Takefumi</creator><creator>Mamo, David C.</creator><creator>Pollock, Bruce G.</creator><creator>Graff-Guerrero, Ariel</creator><creator>Mimura, Masaru</creator><creator>Uchida, Hiroyuki</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>20130801</creationdate><title>Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data</title><author>Tsuboi, Takashi ; Bies, Robert R. ; Suzuki, Takefumi ; Mamo, David C. ; Pollock, Bruce G. ; Graff-Guerrero, Ariel ; Mimura, Masaru ; Uchida, Hiroyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-b6cacae5625b86918949b1d36ae48afeec6ab57dd5499e015e53de732c0943383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Aged</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic Agents - blood</topic><topic>Antipsychotic Agents - pharmacology</topic><topic>Benzodiazepines - adverse effects</topic><topic>Benzodiazepines - blood</topic><topic>Benzodiazepines - pharmacology</topic><topic>Biological and medical sciences</topic><topic>CATIE</topic><topic>Data processing</topic><topic>Dopamine D2 receptor occupancy</topic><topic>Endocrinopathies</topic><topic>Female</topic><topic>Humans</topic><topic>Hyperprolactinemia</topic><topic>Hyperprolactinemia - blood</topic><topic>Hyperprolactinemia - chemically induced</topic><topic>Hyperprolactinemia - complications</topic><topic>Hyperprolactinemia - metabolism</topic><topic>Hypothalamus. Hypophysis. Epiphysis (diseases)</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Non tumoral diseases. Target tissue resistance. Benign neoplasms</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperazines - adverse effects</topic><topic>Piperazines - blood</topic><topic>Piperazines - pharmacology</topic><topic>Predictive Value of Tests</topic><topic>Prolactin - blood</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychoses</topic><topic>Receptors, Dopamine D2 - drug effects</topic><topic>Risperidone - adverse effects</topic><topic>Risperidone - blood</topic><topic>Risperidone - pharmacology</topic><topic>Schizophrenia</topic><topic>Schizophrenia - blood</topic><topic>Schizophrenia - complications</topic><topic>Schizophrenia - metabolism</topic><topic>Sensitivity and Specificity</topic><topic>Thiazoles - adverse effects</topic><topic>Thiazoles - blood</topic><topic>Thiazoles - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tsuboi, Takashi</creatorcontrib><creatorcontrib>Bies, Robert R.</creatorcontrib><creatorcontrib>Suzuki, Takefumi</creatorcontrib><creatorcontrib>Mamo, David C.</creatorcontrib><creatorcontrib>Pollock, Bruce G.</creatorcontrib><creatorcontrib>Graff-Guerrero, Ariel</creatorcontrib><creatorcontrib>Mimura, Masaru</creatorcontrib><creatorcontrib>Uchida, Hiroyuki</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tsuboi, Takashi</au><au>Bies, Robert R.</au><au>Suzuki, Takefumi</au><au>Mamo, David C.</au><au>Pollock, Bruce G.</au><au>Graff-Guerrero, Ariel</au><au>Mimura, Masaru</au><au>Uchida, Hiroyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data</atitle><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><date>2013-08-01</date><risdate>2013</risdate><volume>45</volume><spage>178</spage><epage>182</epage><pages>178-182</pages><issn>0278-5846</issn><eissn>1878-4216</eissn><coden>PNPPD7</coden><abstract>Large-scale data are still lacking on the relationship between serum prolactin concentration and dopamine D2 receptor occupancy in patients with schizophrenia treated with antipsychotics.
The dataset from 481 subjects (risperidone, N=172, olanzapine, N=211, and ziprasidone, N=98) who participated in Phase 1 of the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) was used in the present analysis. Dopamine D2 receptor occupancy levels on the day of the measurement of serum prolactin level were estimated from plasma antipsychotic concentrations. A multivariate general linear model was used to examine effects of clinical and demographic characteristics, including estimated D2 occupancy levels, on serum prolactin concentrations. Individual subjects were divided into two groups, stratified by the presence of hyperprolactinemia. To evaluate the performance of this binary classification, sensitivity, specificity, and accuracy of consecutive cut-off points in the D2 occupancy were calculated.
The multivariate general linear model revealed that estimated D2 occupancy levels had significant effects on serum prolactin concentrations while any other variables failed to show significant effects. The cut-off point associated with 0.5 or greater, in both sensitivity and specificity with the greatest accuracy, was 73% (sensitivity, 0.58; specificity, 0.68; accuracy=0.64) (68–70% for risperidone, 77% for olanzapine, and 55% for ziprasidone.).
The threshold for hyperprolactinemia in D2 occupancy may lie somewhat on a lower side of the established therapeutic window with antipsychotics (i.e. 65–80%). This finding highlights the need for the use of the lowest possible dose to avoid this hormonal side effect in the treatment of schizophrenia.
•We evaluated the relationship between hyperprolactinemia and dopamine D2 occupancy.•The dataset from patients with schizophrenia in the CATIE was used.•D2 receptor occupancy was estimated from plasma concentrations of antipsychotics.•The threshold for hyperprolactinemia in dopamine D2 occupancy was found to be 73%.•The threshold was 68–70% for risperidone, 77% olanzapine, and 55% ziprasidone.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>23727135</pmid><doi>10.1016/j.pnpbp.2013.05.010</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0278-5846 |
ispartof | Progress in neuro-psychopharmacology & biological psychiatry, 2013-08, Vol.45, p.178-182 |
issn | 0278-5846 1878-4216 |
language | eng |
recordid | cdi_proquest_miscellaneous_1500791253 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | Adolescent Adult Adult and adolescent clinical studies Aged Antipsychotic Agents - adverse effects Antipsychotic Agents - blood Antipsychotic Agents - pharmacology Benzodiazepines - adverse effects Benzodiazepines - blood Benzodiazepines - pharmacology Biological and medical sciences CATIE Data processing Dopamine D2 receptor occupancy Endocrinopathies Female Humans Hyperprolactinemia Hyperprolactinemia - blood Hyperprolactinemia - chemically induced Hyperprolactinemia - complications Hyperprolactinemia - metabolism Hypothalamus. Hypophysis. Epiphysis (diseases) Male Medical sciences Middle Aged Neuropharmacology Non tumoral diseases. Target tissue resistance. Benign neoplasms Pharmacology. Drug treatments Piperazines - adverse effects Piperazines - blood Piperazines - pharmacology Predictive Value of Tests Prolactin - blood Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychoses Receptors, Dopamine D2 - drug effects Risperidone - adverse effects Risperidone - blood Risperidone - pharmacology Schizophrenia Schizophrenia - blood Schizophrenia - complications Schizophrenia - metabolism Sensitivity and Specificity Thiazoles - adverse effects Thiazoles - blood Thiazoles - pharmacology |
title | Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T21%3A17%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hyperprolactinemia%20and%20estimated%20dopamine%20D2%20receptor%20occupancy%20in%20patients%20with%20schizophrenia:%20Analysis%20of%20the%20CATIE%20data&rft.jtitle=Progress%20in%20neuro-psychopharmacology%20&%20biological%20psychiatry&rft.au=Tsuboi,%20Takashi&rft.date=2013-08-01&rft.volume=45&rft.spage=178&rft.epage=182&rft.pages=178-182&rft.issn=0278-5846&rft.eissn=1878-4216&rft.coden=PNPPD7&rft_id=info:doi/10.1016/j.pnpbp.2013.05.010&rft_dat=%3Cproquest_cross%3E1500791253%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1412156264&rft_id=info:pmid/23727135&rft_els_id=S027858461300105X&rfr_iscdi=true |